Search

UCB SA

Gesloten

SectorGezondheidszorg

168.9 3.4

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

168.8

Max

169.25

Belangrijke statistieken

By Trading Economics

Inkomsten

857M

Verkoop

3.4B

K/W

Sectorgemiddelde

30.465

40.527

Dividendrendement

0.82

Winstmarge

25.498

Werknemers

9,052

EBITDA

1.3B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+19.23% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

0.82%

2.40%

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-4B

32B

Vorige openingsprijs

165.5

Vorige sluitingsprijs

168.9

Nieuwssentiment

By Acuity

27%

73%

41 / 375 Rangschikking in Healthcare

UCB SA Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 jul 2025, 23:55 UTC

Marktinformatie

Gold Edges Lower on Possible Position Adjustments -- Market Talk

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32 Expects to Complete Transaction in Late 2025

6 jul 2025, 22:35 UTC

Acquisities, Fusies, Overnames

South32: CoreX to Make Future Cash Payments of Up to US$100 Million for Cerro Matoso

6 jul 2025, 22:34 UTC

Acquisities, Fusies, Overnames

South32 Agrees to Sell Cerro Matoso Nickel Operation to Unit of CoreX Holding

5 jul 2025, 04:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

4 jul 2025, 16:20 UTC

Marktinformatie

Health Care Roundup: Market Talk

4 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 15:57 UTC

Marktinformatie

Base Metal Prices Fall in Thin, Risk-off Trading -- Market Talk

4 jul 2025, 15:49 UTC

Marktinformatie

Gold Futures Set to End Week Flat After Mixed Jobs Report -- Market Talk

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Deal Will Have a Negative Impact of Approximately 30 Basis Points on the Fully-Loaded CET1 Ratio

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Transaction Is Consistent With Targets in Terms of Return of Investment, Return on Tangible Equity

4 jul 2025, 15:49 UTC

Acquisities, Fusies, Overnames

Credit Agricole Received All Required Authorizations

4 jul 2025, 15:48 UTC

Acquisities, Fusies, Overnames

Credit Agricole: CACEIS and Santander Are Maintaining Their Long-Term Partnership

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole: Agreement Was Announced on Dec. 19

4 jul 2025, 15:47 UTC

Acquisities, Fusies, Overnames

Credit Agricole Now Controls 100% of the Share Capital of CACEIS

4 jul 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Credit Agricole Completes Acquisition of Santander's 30.5% Stake in CACEIS

4 jul 2025, 14:30 UTC

Acquisities, Fusies, Overnames

Rocky Shore Closes Hemlo Area Claims Sale to Barrick Mining Unit for C$975,000 Cash

4 jul 2025, 13:53 UTC

Marktinformatie

Polish Zloty Faces Hit From Prospect of Further Rate Cuts -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Japanese Yen Could Receive Boost From Increased Rate-Hike Bets -- Market Talk

4 jul 2025, 13:41 UTC

Marktinformatie

Market Talk Roundup: Latest on U.S. Politics

4 jul 2025, 13:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus Amid Rising Debt

4 jul 2025, 12:37 UTC

Marktinformatie

Fund Manager Roundup: U.S. Treasurys in Focus -2-

UCB SA Prognose

Koersdoel

By TipRanks

19.23% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 94.86Ā EURĀ  19.23%

Hoogste 125Ā EUR

Laagste 74Ā EUR

Gebaseerd op 7 Wall Street-analisten die 12-maands prijsdoelen bieden voor UCB SA - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

7 ratings

4

Buy

1

Hold

2

Sell

Sentiment

By Acuity

41 / 375 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over UCB SA

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx for treating plaque psoriasis, psoriatic arthritis, and axial spondyloarthritis; and Fintepla to treat Dravet syndrome. In addition, the company is involved in developing rozanolixizumab and Zilbrisq to treat myasthenia gravis; dapirolizumab pegol for systemic lupus erythematosus; fenfluramine to treat CDKL5 deficiency disorder; doxecitine for TK2 deficiency disorder; STACCATO alprazolam for stereotypical prolonged seizures; bepranemab to treat Alzheimer's disease; minzasolmin and UCB0222 for Parkinson's disease; and UCB1381 and UCB9741 for atropic dermatitis. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, and Otsuka. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.